Jean-Claude Provost - Mar 2, 2023 Form 4 Insider Report for Lantheus Holdings, Inc. (LNTH)

Role
Chief Medical Officer
Signature
/s/ Eric Green, attorney-in-fact
Stock symbol
LNTH
Transactions as of
Mar 2, 2023
Transactions value $
$0
Form type
4
Date filed
3/6/2023, 08:11 PM
Previous filing
Jan 10, 2023
Next filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LNTH Common Stock Award $0 +16.4K +366.47% $0.00 20.8K Mar 2, 2023 By Theranostics Consulting SAS F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LNTH Stock Option (right to buy) Award $0 +9.54K $0.00 9.54K Mar 2, 2023 Common Stock 9.54K $73.35 By Theranostics Consulting SAS F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of 5,453 restricted stock units that vest in equal installments over a three-year period and 10,906 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.
F2 The reporting person is the managing partner of the company that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3 The option vests in three equal annual installments beginning on March 2, 2024.